TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.860
-0.120 (-6.06%)
At close: Mar 10, 2025, 4:00 PM
1.975
+0.115 (6.18%)
Pre-market: Mar 11, 2025, 7:19 AM EST
TScan Therapeutics Stock Forecast
TCRX's stock price has decreased by -71.6% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 9.80, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 426.88% from the current stock price of 1.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TScan Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $14 → $3 | Buy | Maintains | $14 → $3 | +61.29% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +706.45% | Mar 6, 2025 |
| Needham | Needham | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +383.87% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +706.45% | Dec 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +491.40% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
3.72M
from 2.82M
Increased by 32.21%
Revenue Next Year
8.13M
from 3.72M
Increased by 118.35%
EPS This Year
-1.19
from -1.14
EPS Next Year
-1.37
from -1.19
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 22.1M | 77.6M | ||
| Avg | 3.7M | 8.1M | 31.1M | ||
| Low | n/a | n/a | 2.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 272.9% | 492.3% | 855.0% | ||
| Avg | 32.2% | 118.3% | 282.4% | ||
| Low | - | - | -72.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.02 | -0.93 | -0.85 | ||
| Avg | -1.19 | -1.37 | -1.23 | ||
| Low | -1.39 | -1.74 | -1.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.